A radiology committee shall examine tumor scans based on the RECIST requirements. malignancies harboring MET gene CD80 modifications. Methods Co-MET can be an open-label, multi-center, single-arm, stage II trial to measure the protection and effectiveness of dental crizotinib in individuals with advanced non-small cell lung tumor harboring MET exon 14 Continue Reading